Mark J. Suto

Mark J. Suto

Corporate Officer/Principal bij Southern Research Institute

Health Technology
Commercial Services
Consumer Services

Profiel

Mark J.
Suto
currently works at American Chemical Society, as Member and Southern Research Institute, as Vice President-Drug Discovery Division from 2011.
Dr. Suto also formerly worked at DuPont Pharmaceuticals Co., as Executive Director-Chemistry from 1999 to 2002, Neusentis, Inc., as Vice President-Chemical & Pharmaceutical Sciences from 2009 to 2011, Neurion Pharmaceuticals, Inc., as Chief Scientific Officer & EVP in 2002, Deltagen Research Laboratories LLC, as Vice President-Chemical & Biological Sciences, and Parke-Davis Pharmaceutical Research, Inc., as Principal.
Dr. Suto received his undergraduate degree and doctorate degree from The State University of New York.

Actieve functies van Mark J. Suto

BedrijvenFunctieBegin
Corporate Officer/Principal 18-08-2011
Corporate Officer/Principal -
Alle actieve functies van Mark J. Suto

Eerdere bekende functies van Mark J. Suto

BedrijvenFunctieEinde
Corporate Officer/Principal 01-08-2011
Corporate Officer/Principal 01-01-2002
Hoofd Techniek/Wetenschap/O&O 01-01-2002
Parke-Davis Pharmaceutical Research, Inc. Corporate Officer/Principal -
Deltagen Research Laboratories LLC Corporate Officer/Principal -
Ervaring van Mark J. Suto in detail bekijken

Opleiding van Mark J. Suto

The State University of New York Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Mark J. Suto in detail bekijken

Connecties

100 +

Eerstegraads connecties

8

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit7

Health Technology

Health Technology

Commercial Services

Health Technology

Commercial Services

Deltagen Research Laboratories LLC

Parke-Davis Pharmaceutical Research, Inc.

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Mark J. Suto
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU